Resumen
Antifungal therapeutic drug monitoring (TDM) is recommended for hospitalized patients receiving itraconazole, posaconazole, or voriconazole for treatment or prophylaxis. In this analysis of hospital-based data, TDM was uncommonly performed (15.8%) in a large cohort of eligible patients, suggesting missed opportunities to avoid subtherapeutic drug levels and minimize toxicity.
| Idioma original | English (US) |
|---|---|
| Número de artículo | ofad389 |
| Publicación | Open Forum Infectious Diseases |
| Volumen | 10 |
| N.º | 8 |
| DOI | |
| Estado | Published - ago 1 2023 |
ASJC Scopus subject areas
- Oncology
- Infectious Diseases
Huella
Profundice en los temas de investigación de 'Low Rates of Antifungal Therapeutic Drug Monitoring Among Inpatients Who Received Itraconazole, Posaconazole, or Voriconazole, United States, 2019–2021'. En conjunto forman una huella única.Citar esto
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS